Literature DB >> 27306387

Lung Cancer Screening Update.

Kathleen L Ruchalski1, Kathleen Brown.   

Abstract

Since the release of the US Preventive Services Task Force and Centers for Medicare and Medicaid Services recommendations for lung cancer screening, low-dose chest computed tomography screening has moved from the research arena to clinical practice. Lung cancer screening programs must reach beyond image acquisition and interpretation and engage in a multidisciplinary effort of clinical shared decision-making, standardization of imaging and nodule management, smoking cessation, and patient follow-up. Standardization of radiologic reports and nodule management will systematize patient care, provide quality assurance, further reduce harm, and contain health care costs. Although the National Lung Screening Trial results and eligibility criteria of a heavy smoking history are the foundation for the standard guidelines for low-dose chest computed tomography screening in the United States, currently only 27% of patients diagnosed with lung cancer would meet US lung cancer screening recommendations. Current and future efforts must be directed to better delineate those patients who would most benefit from screening and to ensure that the benefits of screening reach all socioeconomic strata and racial and ethnic minorities. Further optimization of lung cancer screening program design and patient eligibility will assure that lung cancer screening benefits will outweigh the potential risks to our patients.

Entities:  

Mesh:

Year:  2016        PMID: 27306387     DOI: 10.1097/RTI.0000000000000221

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  6 in total

1.  Optimizing the lung cancer screening interval: the world is waiting.

Authors:  Carole A Ridge; Phillip M Boiselle
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 2.  The Role of Imaging in Health Screening: Screening for Specific Conditions.

Authors:  David H Ballard; Kirsteen R Burton; Nikita Lakomkin; Shannon Kim; Prabhakar Rajiah; Midhir J Patel; Parisa Mazaheri; Gary J Whitman
Journal:  Acad Radiol       Date:  2020-05-11       Impact factor: 3.173

3.  Histogram-based models on non-thin section chest CT predict invasiveness of primary lung adenocarcinoma subsolid nodules.

Authors:  Anastasia Oikonomou; Pascal Salazar; Yuchen Zhang; David M Hwang; Alexander Petersen; Adam A Dmytriw; Narinder S Paul; Elsie T Nguyen
Journal:  Sci Rep       Date:  2019-04-12       Impact factor: 4.379

4.  Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells.

Authors:  Al Hassan Kyakulaga; Farrukh Aqil; Radha Munagala; Ramesh C Gupta
Journal:  Oncotarget       Date:  2020-04-21

5.  Cell-surface marker discovery for lung cancer.

Authors:  Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse
Journal:  Oncotarget       Date:  2017-12-07

6.  Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells.

Authors:  Al Hassan Kyakulaga; Farrukh Aqil; Radha Munagala; Ramesh C Gupta
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.